1-5 of 5
Timothy H. Brümmendorf
Close
Sort by
Journal Articles

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up

Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Natalia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Rocco J. Crescenzo, DO, FACOI, Eric Leip, PhD, Nathalie Bardy-Bouxin, PhD, Andrea Hochhaus, Prof. Dr., Timothy H. Brümmendorf, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 896.
https://doi.org/10.1182/blood.V130.Suppl_1.896.896
Published: 2017
Journal Articles

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial

Jorge E. Cortes, MD, Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Nataliia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Laurence Reilly, Allison Jeynes-Ellis, Rocco J. Crescenzo, DO, FACOI, Carla Mamolo, Arlene Reisman, Nathalie Bardy-Bouxin, PhD, Andrea Hochhaus, Prof. Dr., Timothy H. Brümmendorf
Journal: Blood
Blood (2017) 130 (Supplement 1): 2895.
https://doi.org/10.1182/blood.V130.Suppl_1.2895.2895
Published: 2017
Journal Articles

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results By 3-Month BCR-ABL1 Transcript Level

Andreas Hochhaus, Prof. Dr., Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Nataliia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Laurence Reilly, Allison Jeynes-Ellis, Rocco J. Crescenzo, DO, FACOI, Eric Leip, PhD, Nathalie Bardy-Bouxin, PhD, Timothy H. Brümmendorf, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1618.
https://doi.org/10.1182/blood.V130.Suppl_1.1618.1618
Published: 2017
Journal Articles

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial

Michael J. Mauro, MD, Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Natalia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Laurence Reilly, Allison Jeynes-Ellis, Rocco J. Crescenzo, DO, FACOI, Roberto Uehara, Eric Leip, PhD, Liza DeAnnuntis, Nathalie Bardy-Bouxin, PhD, Andreas Hochhaus, MD, Timothy H. Brümmendorf, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1620.
https://doi.org/10.1182/blood.V130.Suppl_1.1620.1620
Published: 2017
Journal Articles

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Francis J. Giles, MB, MD FRCPI, FRCPath, Delphine Rea, MD PhD, Michele Baccarani, Nicholas C.P. Cross, PhD, Juan Luis Steegmann, MD, Laimonas Griskevicius, Philipp le Coutre, Daniel Coriu, Ljubomir Petrov, MD PhD, Gert J. Ossenkoppele, MD PhD, Francois-Xavier Mahon, Martin C. Müller, MD, Andrzej Hellmann, MD PhD, Kimmo Porkka, MD PhD, Timothy H. Brümmendorf, Gunther Gastl, MD Prof,, Viviana Tubazio, Angela Pellegrino, Luca Dezzani, Gianantonio Rosti, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2015) 126 (23): 479.
https://doi.org/10.1182/blood.V126.23.479.479
Published: 2015